文献速递腹部技术与安全USCTMR

2017版美国肝脏影像报告和数据系统在肝细胞癌高危人群中的验证

Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma.
PubMed 文献 · Radiology · 2019-06-18

本研究纳入407例前瞻性招募的肝硬化肝细胞癌高危参与者,两名放射科医生回顾性分析超声图像并赋予US LI-RADS类别和可视化评分。US-3类诊断肝细胞癌特异度高但敏感度低,可视化评分C的假阴性率最高,高体重、Child-Pugh B级和中重度脂肪肝与可视化评分C相关。

要点

  • US-3类诊断肝细胞癌特异度高(病灶分析92%,患者分析93%)但敏感度低(病灶分析34%,患者分析39%)。
  • 可视化评分C的假阴性率最高(7例中6例,86%)。
  • 高体重、Child-Pugh B级和中重度脂肪肝与可视化评分C相关。

核心结论

  • US-3类诊断肝细胞癌表现出高特异度但低敏感度。
  • 可视化评分C的假阴性率高于评分A或B,高体重、Child-Pugh B级疾病和中重度脂肪肝患者可能对超声监测存在限制。

研究设计与样本

  • 本研究为前瞻性招募参与者的回顾性图像分析,纳入407例肝硬化肝细胞癌高危参与者(平均年龄56岁,范围28-76岁),于2011年11月至2012年8月接受超声监测。
  • 两名放射科医生回顾性分析超声图像,赋予LI-RADS类别(US-1=阴性,US-2=低于阈值,US-3=阳性)和可视化评分(A=无或轻微限制,B=中度限制,C=严重限制)。
  • 以病理结果和典型CT或MRI为参考标准,计算诊断肝细胞癌的敏感度和特异度(按患者和按病灶分析),并通过单变量和多变量分析确定可视化评分差的危险因素。

诊断标准与关键数值

  • 按病灶分析,US-3诊断肝细胞癌的特异度为366/397(92%;95%CI:89%,95%),敏感度为11/32(34%;95%CI:20%,52%)。
  • 按患者分析,US-3诊断肝细胞癌的特异度为352/379(93%;95%CI:90%,95%),敏感度为11/28(39%;95%CI:24%,58%)。
  • 可视化评分C(407例中114例[28%])的假阴性率最高(7例中6例[86%])。

临床应用与阅片要点

  • US-3类可用于确认肝细胞癌但敏感度低,阴性或低于阈值结果不能排除肝细胞癌。
  • 可视化评分C提示超声监测限制大、假阴性率高,高体重、Child-Pugh B级和中重度脂肪肝患者可能出现监测限制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The 2017 version of the Liver Imaging Reporting and Data System (LI-RADS) recently included standardized interpretation, reporting, and management guidelines for US (US LI-RADS); however, this system has not yet been validated. Purpose To evaluate the diagnostic performance of US LI-RADS version 2017 for detecting hepatocellular carcinoma (HCC) in participants at high risk and to determine the clinical factors associated with a poor visualization score. Materials and Methods This study included 407 prospectively recruited participants (mean age, 56 years; age range, 28-76 years) with cirrhosis at high risk for HCC who underwent US surveillance from November 2011 to August 2012. Two radiologists retrospectively analyzed US images, assigning a LI-RADS category (US-1 = negative, US-2 = subthreshold, US-3 = positive) and a visualization score (A = no or minimal limitations, B = moderate limitations, C = severe limitations). The sensitivity and specificity for diagnosing HCC were calculated on a per-patient and per-lesion basis, using pathologic results and typical CT or MRI as reference standards. The risk factors for a poor visualization score were determined by using univariable and multivariable analyses. Results Of 429 lesions in 407 participants, there were 32 HCCs in 28 participants. In the per-lesion analysis, the specificity for US-3 was 366 of 397 (92%; 95% confidence interval [CI]: 89%, 95%) and the sensitivity was 11 of 32 (34%; 95% CI: 20%, 52%). In the per-patient analysis, the specificity for US-3 was 352 of 379 (93%; 95% CI: 90%, 95%) and the sensitivity was 11 of 28 (39%; 95% CI: 24%, 58%). Visualization score C (114 of 407 [28%] participants) had the highest false-negative rate (six of seven [86%] participants). High body weight (adjusted odds ratio [OR], 2.1 [95% CI: 1.2, 3.6]; P = .01), Child-Pugh class B disease (OR, 2.9 [95% CI: 1.7, 4.9]; P < .001), and moderate to severe fatty liver (OR, 1.7 [95% CI: 1.0, 2.8]; P = .047) were associated with a poor visualization score of C. Conclusion The US-3 category demonstrated high specificity but low sensitivity for diagnosing hepatocellular carcinoma. The visualization score C had a higher false-negative rate than scores A or B, and patients with high body weight, Child-Pugh class B disease, and moderate to severe fatty liver may present limitations for US surveillance. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Milot in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Son JH, Choi SH, Kim SY, et al. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology. 2019. PMID: 31210614. doi:10.1148/radiol.2019190035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。